The effect of 5alpha-reductase inhibition with dutasteride and finasteride on bone mineral density, serum lipoproteins, hemoglobin, prostate specific antigen and sexual function in healthy young men.
OBJECTIVE
Dutasteride and finasteride are 5alpha-reductase inhibitors that dramatically decrease serum levels of dihydrotestosterone. Because androgens affect bone, lipids, hematopoiesis, prostate and sexual function, we determined the impact of 5alpha-reductase inhibitors on these end points.


METHODS
We conducted a randomized, double-blinded, placebo controlled trial of 99 men 18 to 55 years old randomly assigned to receive 0.5 mg dutasteride (33), 5 mg finasteride (34) or placebo (32) daily for 1 year. Bone mineral density was measured at baseline, after 1 year of treatment and 6 months after drug discontinuation. In addition, markers of bone turnover, fasting serum lipoprotein concentrations, hemoglobin and prostate specific antigen were measured at baseline, after 26 and 52 weeks of treatment, and again 24 weeks after drug discontinuation. Sexual function was assessed at these points by a validated questionnaire.


RESULTS
Significant suppression of circulating dihydrotestosterone levels with the administration of dutasteride or finasteride did not significantly affect bone mineral density or markers of bone metabolism. Similarly serum lipoproteins and hemoglobin were unaffected. Serum prostate specific antigen and self-assessed sexual function decreased slightly during treatment with both 5alpha-reductase inhibitors but returned to baseline during followup.


CONCLUSIONS
Profound suppression of circulating serum dihydrotestosterone induced by 5alpha-reductase inhibitors during 1 year does not adversely impact bone, serum lipoproteins or hemoglobin, and has a minimal, reversible effect on serum prostate specific antigen and sexual function in normal men. Circulating dihydrotestosterone does not appear to have a clinically significant role in modulating bone mass, hematopoiesis or lipid metabolism in normal men.
Amory
John K
JK
Department of Medicine, University of Washington, Seattle, Washington, USA.
Anawalt
Bradley D
BD
Matsumoto
Alvin M
AM
Page
Stephanie T
ST
Bremner
William J
WJ
Wang
Christina
C
Swerdloff
Ronald S
RS
Clark
Richard V
RV
D000293:Adolescent; D000328:Adult; D001378:Azasteroids / Q000494:pharmacology*; D015519:Bone Density / Q000187:drug effects*; D042944:Cholestenone 5 alpha-Reductase / Q000037:antagonists & inhibitors*; D004311:Double-Blind Method; D000068538:Dutasteride; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D018120:Finasteride / Q000494:pharmacology*; D006454:Hemoglobins / Q000032:analysis* / Q000187:drug effects*; D006801:Humans; D008074:Lipoproteins / Q000097:blood* / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000097:blood* / Q000187:drug effects*; D019529:Sexuality / Q000187:drug effects*
D001378:Azasteroids; D004791:Enzyme Inhibitors; D006454:Hemoglobins; D008074:Lipoproteins; D018120:Finasteride; D042944:Cholestenone 5 alpha-Reductase; D017430:Prostate-Specific Antigen; D000068538:Dutasteride